BCAT2 and gastric cancer: Collectively, our findings revealed that SRSF10 orchestrates mTOR-CCL2 signaling by alternative RNA splicing of BCAT2 to reprogram TAMs, proposing SRSF10 as a tempting therapeutic target for GC immunotherapy.